Acute myeloid leukaemia.
Acute myeloid leukaemia.
复制标题
DOI：
10.1016/s0140-6736(18)31041-9
复制
发表时间：
2018-08-18
期刊：
影响因子：
168.9
通讯作者：
Cortes, Jorge E.
中科院分区：
文献类型：
--
作者：
Short, Nicholas J.;Rytting, Michael E.;Cortes, Jorge E.
几十年来，急性髓性白血病患者的治疗进展很少。然而，自2017年以来，可用于治疗急性髓系白血病的药物数量出现了前所未有的增长，有几种新药获得了监管部门的批准。除了推进我们的治疗方法外，对急性髓系白血病生物学和基因组结构的进一步了解导致了对该疾病的精细风险评估，目前共识风险分层指南纳入了越来越多的复发性分子畸变，有助于选择风险适应性管理策略。尽管最近取得了令人鼓舞的进展，但急性髓性白血病患者的结局仍不令人满意，超过一半的患者最终死于疾病。为了继续取得进展并进一步改善急性髓性白血病患者的预后，必须让患者参加评估新药和合理联合治疗的临床试验。
For several decades, few substantial therapeutic advances have been made for patients with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen in the number of drugs available for the treatment of acute myeloid leukaemia, with several new drugs receiving regulatory approval. In addition to advancing our therapeutic armamentarium, an increased understanding of the biology and genomic architecture of acute myeloid leukaemia has led to refined risk assessment of this disease, with consensus risk stratification guidelines now incorporating a growing number of recurrent molecular aberrations that aid in the selection of risk-adapted management strategies. Despite this promising recent progress, the outcomes of patients with acute myeloid leukaemia remain unsatisfactory, with more than half of patients ultimately dying from their disease. Enrolment of patients into clinical trials that evaluate novel drugs and rational combination therapies is imperative to continuing this progress and further improving the outcomes of patients with acute myeloid leukaemia.